Emricasan
Emricasan[edit | edit source]
Emricasan is a small-molecule caspase inhibitor that has been investigated for its potential therapeutic effects in various liver diseases. It is designed to reduce inflammation and apoptosis by inhibiting the activity of caspases, which are enzymes involved in the process of programmed cell death.
Mechanism of Action[edit | edit source]
Emricasan works by targeting and inhibiting specific caspases, particularly caspase-3 and caspase-7, which play a crucial role in the execution phase of apoptosis. By inhibiting these enzymes, Emricasan aims to prevent the cascade of events that lead to cell death, thereby reducing tissue damage and inflammation in affected organs.
Clinical Applications[edit | edit source]
Emricasan has been studied primarily in the context of chronic liver disease, including conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. The drug's ability to modulate apoptosis and inflammation makes it a promising candidate for treating these conditions, which are characterized by excessive cell death and inflammatory responses.
Non-Alcoholic Steatohepatitis (NASH)[edit | edit source]
In NASH, Emricasan is being evaluated for its potential to reduce liver inflammation and fibrosis. NASH is a progressive form of non-alcoholic fatty liver disease (NAFLD) that can lead to cirrhosis and liver failure if left untreated.
Liver Fibrosis and Cirrhosis[edit | edit source]
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, which can lead to cirrhosis, a severe scarring of the liver. Emricasan's role in inhibiting apoptosis may help slow or reverse the progression of fibrosis and cirrhosis by reducing the death of liver cells and subsequent fibrotic response.
Development and Research[edit | edit source]
Emricasan has undergone various clinical trials to assess its safety and efficacy in patients with liver diseases. These studies aim to determine the optimal dosing, potential side effects, and overall impact on liver function and disease progression.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
